http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2000507912-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1647 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-54 |
| filingDate | 1996-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2000-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2000507912-A |
| titleOfInvention | Sustained release composition of active agent |
| abstract | (57) [Summary]nAn in vivo sustained release composition of a bioactive agent. The composition comprises a first biocompatible solid phase material and a bioactive agent, and a microcarrier that maintains in vivo release of the bioactive agent. The composition also includes particles of a second biocompatible solid phase material that further maintain in vivo release of the bioactive agent. The invention also includes forming an injectable dose comprising an effective amount of a bioactive agent contained in a microcarrier with an amount of a solid phase material that maintains a release period, wherein the effective serum of the bioactive agent in the patient is provided. It also concerns how to maintain levels. The method further includes administering the injectable dose to the patient. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006525319-A |
| priorityDate | 1995-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 166.